恩替卡韦相关的中毒性表皮坏死松解症1例报告并文献复习

鲁瑞; 耿晓珍; 党双锁; 王文俊

doi:10.3969/j.issn.1001-5256.2022.06.027

恩替卡韦相关的中毒性表皮坏死松解症1例报告并文献复习

DOI: 10.3969/j.issn.1001-5256.2022.06.027

西安交通大学第二附属医院感染科，西安 710004

基金项目:

中国肝炎防治基金会-天晴肝病研究基金资助课题 (TQGB20180175)

伦理学声明：本例报告已获得患者知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：鲁瑞负责个案资料的整理和论文初稿的撰写; 耿晓珍负责文献复习，参与个案资料的核对和论文讨论; 党双锁指导论文的写作; 王文俊负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
王文俊，wenjun_wang@xjtu.edu.cn

计量
- 文章访问数: 538
- HTML全文浏览量: 129
- PDF下载量: 60
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-25
- 录用日期: 2021-09-26
- 出版日期: 2022-06-20

Toxic epidermal necrolysis related to entecavir: A case report and literature review

Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

Research funding:

Chinese Foundation for Hepatitis Prevention and Control: TianQing Liver Disease Research Fund Subject (TQGB20180175)

More Information

Corresponding author: WANG Wenjun, wenjun_wang@xjtu.edu.cn(ORCID: 0000-0001-9861-1763)

摘要

- 恩替卡韦 /
- 表皮坏死松解症, 中毒性 /
- 乙型肝炎病毒
- Entecavir /
- Epidermal Necrolysis, Toxic /
- Hepatitis B virus

HTML全文

表 1 恩替卡韦相关皮肤不良反应的个案报道

Table 1. Case reports of cutaneous adverse reactions related to entecavir

作者和年份	国家	年龄(岁)	性别	皮疹类型	皮疹部位	暴露至发病时	DLST/ 斑贴试验/ 划痕试验	抗病毒药	治疗方法	皮疹结局
王丽君，2011^[3]	中国	39	男	TEN	颜面、躯干、四肢	7 d	未做	停恩替卡韦，换拉米夫定联合阿德福韦酯	糖皮质激素静脉滴注，抗组胺药口服	皮疹消退
Sugiura K，2009^[8]	日本	30	男	速发型皮肤过敏反应	臀部	2 d	划痕试验+ 斑贴试验-	停恩替卡韦，换拉米夫定	皮质类固醇外用，抗组胺药口服	皮疹消退
Yamada S，2011^[9]	日本	62	男	斑丘疹	躯干、四肢	7 d	DLST+	停恩替卡韦	皮质类固醇外用	皮疹消退
Yoon J，2013^[10]	韩国	65	女	肉芽肿	面部	2个月	斑贴试验-	停恩替卡韦	甲硝唑和防晒霜外用，米诺环素口服	二次服用恩替卡韦皮疹复发，停药及对症处理后皮疹完全消失
Taura M，2014^[11]	日本	65	男	红斑	双上肢	6个月	DLST+	恩替卡韦减量(0.5 mg隔日)	皮质类固醇外用	皮疹减轻，未完全消退
Kim J，2014^[12]	韩国	45	女	斑丘疹	背部、四肢	7 d	DLST+	停恩替卡韦，换拉米夫定联合阿德福韦酯	糖皮质激素和抗组胺药口服	皮疹消退
Temiz S，2018^[13]	土耳其	50	女	大疱型皮疹	右腿	7 d	未做	停恩替卡韦，换拉米夫定联合阿德福韦酯	皮质类固醇外用，抗组胺药口服	皮疹消退
Cheong X，2020^[14]	马来西亚	55	男	苔藓样红斑	躯干、四肢	6周	未做	停恩替卡韦，换富马酸丙酚替诺福韦	糖皮质激素口服，润肤霜外用	皮疹消退
本例	中国	26	男	TEN	颜面、躯干、四肢	1个月	未做	停恩替卡韦，换富马酸丙酚替诺福韦	血浆置换，静脉滴注人免疫球蛋白，糖皮质激素静脉滴注和口服，夫西地酸乳膏和复方黄柏液外用	皮疹消退

下载: 导出CSV

参考文献(18)

[1]	Chinese Society of Infectious Diseases, Chinese Society of Hepatology. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Chin J Dermatol, 2021, 54(5): 376-381. DOI: 10.35541/cjd.20201177. 中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 376-381. DOI: 10.35541/cjd.20201177.
[3]	WANG LJ, ZHAN HQ. Toxic epidermal necrolysis related to entecavir[J]. ADRJ, 2012, 14(6): 186-187. DOI: 10.3969/j.issn.1008-5734.2012.03.018. 王丽君, 战寒秋. 恩替卡韦相关中毒性表皮坏死松解症[J]. 药物不良反应杂志, 2012, 14(6): 186-187. DOI: 10.3969/j.issn.1008-5734.2012.03.018.
[4]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[5]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[6]	MAZZUCCO CE, HAMATAKE RK, COLONNO RJ, et al. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition[J]. Antimicrob Agents Chemother, 2008, 52(2): 598-605. DOI: 10.1128/AAC.01122-07.
[7]	MANNS MP, AKARCA US, CHANG TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901[J]. Expert Opin Drug Saf, 2012, 11(3): 361-368. DOI: 10.1517/14740338.2012.653340.
[8]	SUGIURA K, SUGIURA M, TAKASHI T, et al. Immediate allergy, drug-induced eruption, by entecavir[J]. J Eur Acad Dermatol Venereol, 2009, 23(4): 487-489. DOI: 10.1111/j.1468-3083.2008.02932.x.
[9]	YAMADA S, SAWADA Y, NAKAMURA M. Maculopapular-type drug eruption caused by entecavir[J]. Eur J Dermatol, 2011, 21(4): 635-636. DOI: 10.1684/ejd.2011.1411.
[10]	YOON J, PARK D, KIM C. A granulomatous drug eruption induced by entecavir[J]. Ann Dermatol, 2013, 25(4): 493-495. DOI: 10.5021/ad.2013.25.4.493.
[11]	TAURA M, ASAI J, CHO Z, et al. Drug eruption due to entecavir: A case report and mini-review[J]. Allergol Int, 2016, 65(3): 334-335. DOI: 10.1016/j.alit.2015.12.008.
[12]	KIM JT, JEONG HW, CHOI KH, et al. Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B[J]. World J Gastroenterol, 2014, 20(42): 15931-15936. DOI: 10.3748/wjg.v20.i42.15931.
[13]	TEMIZ SA, ÖZER I ·, ATASEVEN A, et al. A case of entecavir-associated bullous fixed drug eruption and a review of literature[J]. Turk J Gastroenterol, 2019, 30(3): 299-302. DOI: 10.5152/tjg.2018.17887.
[14]	CHEONG XK, WONG Z, NOR NM, et al. "Black box warning" rash with entecavir-case report[J]. BMC Gastroenterol, 2020, 20(1): 305. DOI: 10.1186/s12876-020-01452-3.
[15]	HSU DY, BRIEVA J, SILVERBERG NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults[J]. J Invest Dermatol, 2016, 136(7): 1387-1397. DOI: 10.1016/j.jid.2016.03.023.
[16]	LERCH M, MAINETTI C, TERZIROLI BERETTA-PICCOLI B, et al. Current Perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Clin Rev Allergy Immunol, 2018, 54(1): 147-176. DOI: 10.1007/s12016-017-8654-z.
[17]	KANG DY, YUN J, LEE SY, et al. A nationwide study of severe cutaneous adverse reactions based on the multicenter registry in Korea[J]. J Allergy Clin Immunol Pract, 2021, 9(2): 929-936. e7. DOI: 10.1016/j.jaip.2020.09.011.
[18]	YE YJ, ZHU YP, XU AE. Clinical analysis of 73 patients with Stevens Johnson syndrome or toxic epidermal necrolysis[J]. Chin J Gen Pract, 2017, 15(10): 1691-1693, 1794. DOI: 10.16766/j.cnki.issn.1674-4152.2017.10.016. 叶瑜剑, 祝逸平, 许爱娥. 重症多形红斑及中毒性表皮坏死松解症73例临床分析[J]. 中华全科医学, 2017, 15(10): 1691-1693, 1794. DOI: 10.16766/j.cnki.issn.1674-4152.2017.10.016.